{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:19:50Z","timestamp":1789057190063,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biotechnology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jbiotec.2020.01.015","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T22:30:52Z","timestamp":1580337052000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X\u2122 hydro fixed-bed"],"prefix":"10.1016","volume":"310","author":[{"given":"Sascha","family":"Kiesslich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Pedro","family":"Vila-Ch\u00e3 Losa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-5781","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"G\u00e9linas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-8815","authenticated-orcid":false,"given":"Amine A.","family":"Kamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbiotec.2020.01.015_bib0005","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV ebola vaccine in Africa and Europe","volume":"347","author":"Agnandji","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/9780471729259.mca04es11","article-title":"Growth and maintenance of Vero cell lines","volume":"11","author":"Ammerman","year":"2008","journal-title":"Curr. Protoc. Microbiol."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Expert Rev. Vacc."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jbiotec.2018.11.023","article-title":"Optimization of production of vesicular stomatitis virus (VSV) in suspension serum-free culture medium at high cell density","volume":"289","author":"Elahi","year":"2019","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/biot.201500176","article-title":"Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells","volume":"11","author":"Emmerling","year":"2016","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0030","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1016\/j.vaccine.2019.09.044","article-title":"Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells","volume":"37","author":"G\u00e9linas","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0035","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0045","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmacol."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0050","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/bit.260100607","article-title":"The cultivation of animal cells at controlled dissolved oxygen partial pressure","volume":"10","author":"Kilburn","year":"1968","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/hum.2015.081","article-title":"Process development of adenoviral vector production in fixed bed bioreactor: from bench to commercial scale","volume":"26","author":"Lesch","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2004.03.003","article-title":"Vesicular stomatitis virus: Re-inventing the bullet","volume":"10","author":"Lichty","year":"2004","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0065","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1016\/j.vaccine.2015.04.050","article-title":"Increasing Vero viable cell densities for yellow fever virus production in stirred-tank bioreactors using serum-free medium","volume":"33","author":"Mattos","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/hgtb.2019.038","article-title":"Transient lentiviral vector production using a packed-bed bioreactor system","volume":"30","author":"McCarron","year":"2019","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0168-1656(02)00048-2","article-title":"Metabolic active-high density VERO cell cultures on microcarriers following apoptosis prevention by galactose\/glutamine feeding","volume":"97","author":"Mendon\u00e7a","year":"2002","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0080","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0040","article-title":"Advances in cell culture: anchorage dependence","volume":"370","author":"Merten","year":"2015","journal-title":"Philos. Trans. R. Soc. B: Biol. Sci."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2019.100009","article-title":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with ebola zaire glycoprotein: standardized template with key considerations for a risk\/benefit assessment","author":"Monath","year":"2019","journal-title":"Vaccine X 1"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0090","series-title":"Cell Culture Technology for Pharmaceutical and Cell-based Therapies","author":"Ozturk","year":"2005"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/hgtb.2016.021","article-title":"Development and optimization of AAV hFIX particles by transient transfection in an iCELLis\u00ae fixed bed bioreactor","volume":"27","author":"Powers","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus ebola vaccine","volume":"376","author":"Regules","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0105","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/j.vaccine.2007.01.086","article-title":"A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions","volume":"25","author":"Rourou","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00253-009-2064-y","article-title":"A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor","volume":"85","author":"Rourou","year":"2009","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0115","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.1016\/j.vaccine.2019.07.003","article-title":"Development of suspension adapted Vero cell culture process technology for production of viral vaccines","volume":"37","author":"Shen","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0120","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1073\/pnas.94.26.14764","article-title":"A system for functional analysis of Ebola virus glycoprotein","volume":"94","author":"Takada","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0125","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.vaccine.2014.02.022","article-title":"Improved poliovirus d-antigen yields by application of different Vero cell cultivation methods","volume":"32","author":"Thomassen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.enzmictec.2004.11.008","article-title":"Comparison of various culture modes for the production of rabies virus by Vero cells grown on microcarriers in a 2-l bioreactor","volume":"36","author":"Trabelsi","year":"2005","journal-title":"Enzyme Microb. Technol."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bej.2014.06.001","article-title":"Process intensification for an enhanced replication of a newly adapted RM-65 sheep pox virus strain in Vero cells grown in stirred bioreactor","volume":"90","author":"Trabelsi","year":"2014","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/gt.2017.91","article-title":"Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor","volume":"25","author":"Valkama","year":"2018","journal-title":"Gene Ther."},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0145","series-title":"Situation Report: Ebola Virus Disease 10 June 2016","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0150","series-title":"Ebola Virus Desease. Democratic Republic of the Congo: External Situation Report 38","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0155","series-title":"Statement on the Meeting of the International Health Regulations (2005) Emergency Committee for Ebola Virus Disease in the Democratic Republic of the Congo on 17 July 2019","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.jbiotec.2020.01.015_bib0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vetmic.2012.08.023","article-title":"Stability and inactivation of vesicular stomatitis virus, a prototype rhabdovirus","volume":"162","author":"Zimmer","year":"2013","journal-title":"Vet. Microbiol."}],"container-title":["Journal of Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165620300171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165620300171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:51:01Z","timestamp":1759150261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168165620300171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":32,"alternative-id":["S0168165620300171"],"URL":"https:\/\/doi.org\/10.1016\/j.jbiotec.2020.01.015","relation":{},"ISSN":["0168-1656"],"issn-type":[{"value":"0168-1656","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X\u2122 hydro fixed-bed","name":"articletitle","label":"Article Title"},{"value":"Journal of Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbiotec.2020.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}